Filtered By:
Condition: Diabetes
Drug: Fortamet

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 393 results found since Jan 2013.

Substance found in red wine 'helps fight ageing'
Conclusion Resveratrol has been of interest to anti-ageing scientists for many years and researchers have previously shown it may be linked to a slowing of the decline in thinking and movement, at least in rodents. This study suggests a possible way this might happen. But the results don't tell us anything about what happens in humans. They suggest this substance may be useful for further research in humans at some point. They certainly don't provide a reason to drink gallons of red wine, in the hope of seeing an anti-ageing effect. Drinking too much alcohol is a sure-fire way to speed up deterioration of thinking skills,...
Source: NHS News Feed - March 8, 2017 Category: Consumer Health News Tags: Food/diet Lifestyle/exercise Neurology Source Type: news

Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second ‐ and third‐line antidiabetic drugs in patients with type 2 diabetes
ConclusionsDPP4is as a second‐ or third‐line add‐on treatment provided cardiovascular benefits and posed no increased risks for heart failure, hypoglycaemia or death.
Source: British Journal of Clinical Pharmacology - February 26, 2017 Category: Drugs & Pharmacology Authors: Huang ‐Tz Ou, Kai‐Cheng Chang, Chung‐Yi Li, Jin‐Shang Wu Tags: DRUG SAFETY Source Type: research

Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care ‐based cohort study, with economic assessment of patient outcomes
ConclusionsWith respect to treatment choice, data from the present study support the notion of prescribing beyond metformin + SU, as alternative regimens have been shown to be associated with reduced outcomes risk and value for money.
Source: Diabetes, Obesity and Metabolism - February 22, 2017 Category: Endocrinology Authors: Jason Gordon, Phil McEwan, Marc Evans, Jorge Puelles, Alan Sinclair Tags: ORIGINAL ARTICLE Source Type: research

Role of Nrf2 and protective effects of Metformin against tobacco smoke-induced cerebrovascular toxicity
Publication date: August 2017 Source:Redox Biology, Volume 12 Author(s): Shikha Prasad, Ravi K. Sajja, Mohammad Abul Kaisar, Jee Hyun Park, Heidi Villalba, Taylor Liles, Thomas Abbruscato, Luca Cucullo Cigarette smoking (CS) is associated with vascular endothelial dysfunction in a causative way primarily related to the TS content of reactive oxygen species (ROS), nicotine, and inflammation. TS promotes glucose intolerance and increases the risk of developing type-2 diabetes mellitus (2DM) with which it shares other pathogenic traits including the high risk of cerebrovascular and neurological disorders like stroke via ROS ...
Source: Redox Biology - February 15, 2017 Category: Biology Source Type: research

Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes
Publication date: Available online 26 January 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Eberhard Standl, Oliver Schnell, Darren K McGuire, Antonio Ceriello, Lars Rydén Cardiovascular outcome trials of antihyperglycaemic drugs and non-statin LDL-cholesterol-lowering drugs in patients with type 2 diabetes who have, or who are at high risk of, atherosclerotic cardiovascular disease have provided new evidence that has substantially affected the management of cardiovascular risk in these patients. On the basis of proven cardiovascular and renal benefit, the antihyperglycaemic drugs empagliflozin, lira...
Source: The Lancet Diabetes and Endocrinology - January 25, 2017 Category: Endocrinology Source Type: research

Comparative cardiovascular risks of dipeptidyl peptidase ‐4 inhibitors with other 2nd and 3rd line antidiabetic drugs in patients with type 2 diabetes
ConclusionsDPP4i as 2nd and 3rd add‐on treatment provided cardiovascular benefits and posed no increased risks for heart failure, hypoglycemia and death.
Source: British Journal of Clinical Pharmacology - January 21, 2017 Category: Drugs & Pharmacology Authors: Huang ‐Tz Ou, Kai‐Cheng Chang, Chung‐Yi Li, Jin‐Shang Wu Tags: DRUG SAFETY Source Type: research

Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
This article reviews evidence of benefits and risk of antidiabetic agents in cardiovascular (CV) outcomes, with a focus on medications approved by the FDA since 2008. Peer-reviewed articles were identified from MEDLINE and Current Content database (both 1966 to October 1, 2016) using the search terms insulin, metformin, rosiglitazone, pioglitazone, glyburide, glipizide, glimepiride, acarbose, miglitol, albiglutide, exenatide, liraglutide, lixisenatide, dulaglutide, pramlintide, meglitinide, alogliptin, linagliptin, saxagliptin, sitagliptin, canagliflozin, dapagliflozin, empagliflozin, colesevalam, bromocriptine, mortality,...
Source: Current Medical Research and Opinion - January 19, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care based cohort study, with economic assessment of patient outcomes
ConclusionsWith respect to treatment choice, data from this study supports the notion of prescribing beyond M+SU, as alternative regimens have been demonstrated to be associated with reduced outcomes risk and value for money.
Source: Diabetes, Obesity and Metabolism - December 26, 2016 Category: Endocrinology Authors: Jason Gordon, Phil McEwan, Marc Evans, Jorge Puelles, Alan Sinclair Tags: ORIGINAL ARTICLE Source Type: research

Sex differences in outcomes after stroke among patients with low total cholesterol levels: a large hospital-based prospective study
ConclusionsThese findings suggest that patients (both men and women) with atherothrombotic infarction who have low TC levels would not benefit from receiving statin treatment. Therefore, it is crucial to explore the impact of statin treatment on outcomes in Asian patients, especially Chinese patients with atherothrombotic and low TC levels, in order to improve outcomes after stroke and reduce the disease burden.
Source: Biology of Sex Differences - November 23, 2016 Category: Biology Source Type: research

Existing evidence is insufficient to justify metformin or other agents as first-line therapy for type 2 diabetes
Commentary on: Palmer SC, Mavridis D, Nicolucci A, et al.. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 2016;316:313–324 . Context A broad consensus supports the use of metformin as first-line therapy for patients with type 2 diabetes. Clinicians and patients, however, may be interested in using newer antihyperglycaemic drugs as first-line treatment, but their relative advantages to metformin—beyond burden of treatment and hypoglycaemic potential—remain uncertain. The systematic review by Palmer et al soug...
Source: Evidence-Based Medicine - November 22, 2016 Category: Internal Medicine Authors: Rodriguez-Gutierrez, R., Montori, V. M. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Diabetes Therapeutics/Prevention Source Type: research

Stroke risk in treatment of type 2 diabetes in China: a 7 year retrospective cohort study
Publication date: November 2016 Source:The Lancet Diabetes & Endocrinology, Volume 4, Supplement 1 Author(s): Rui Liu, Qing Wang, Vivian Szeto, Andrew Barszczyk, Tianru Jin, Edoardo Mannucci, Hong-Shuo Sun, Zhong-Ping Feng Background Diabetes and stroke are leading causes of death and disability, and major public health concerns in China, which accounts for 25% of patients with diabetes worldwide. Type 2 diabetes is an independent risk factor for cerebral ischaemia and accounts for about 20% of stroke cases. We previously showed that KATP channel activation provides neuroprotection against cerebral ischaemia and t...
Source: The Lancet Diabetes and Endocrinology - November 17, 2016 Category: Endocrinology Source Type: research

Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study
This study provides reassurance of the overall safety of insulin use in the treatment of type 2 diabetes and contributes to our understanding of the contrasting conclusions from non-randomised and randomised studies regarding dose-dependent effects of insulin on cardiovascular events and mortality. Funding Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, and the Newfoundland and Labrador Research and Development Corporation.
Source: The Lancet Diabetes and Endocrinology - November 16, 2016 Category: Endocrinology Source Type: research

Cardiovascular Effects of Glucose-Lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
Abstract PURPOSE: The purpose of this study was to review the results of clinical trials assessing the cardiovascular effects of drugs for type 2 diabetes and the cardiovascular effects of newer available drugs. METHODS: We performed a detailed search of PubMed-listed publications, reports from international meetings, and ongoing studies from clinical trials.gov. FINDINGS: Currently available drugs have neutral or, in some cases, negative effects on cardiovascular outcomes. Modern sulfonylureas appear to be safe, although the biguanide metformin has a slightly better cardiovascular safety profile than th...
Source: Clinical Therapeutics - November 14, 2016 Category: Drugs & Pharmacology Authors: Thompson PL, Davis TM Tags: Clin Ther Source Type: research

Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
ConclusionsThese data provide evidence that treatment with liraglutide is associated with improvement of cardiac function and functional capacity in failing post-ischemic type-2 diabetes mellitus patients.
Source: Endocrine - November 8, 2016 Category: Endocrinology Source Type: research

Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
CONCLUSION: These findings suggest that in T2DM subjects on metformin, BQR therapy may represent an effective strategy for reducing CVD risk. PMID: 27687032 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - October 2, 2016 Category: Internal Medicine Tags: Postgrad Med Source Type: research